Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 3/17/20 (What's New)

References

Ait-Khaled M, Nascimento MC, Pappa KA, et al. Switching to DTG/3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 48 weeks: subgroup analyses from the TANGO study. Programs and abstracts of 2019 European AIDS Conference; November 6-9, 2019; Basel, Switzerland. Abstract PS7/2.[Ait-Khaled 2019]

Antinori A, Arribas JR, Fehr J, et al. Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. AIDS. 2015;29:1811-1820.[Antinori 2015]

Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept, pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005;40:280-287.[Arribas 2005]

...

Action required